Structure Therapeutics Inc (GPCR) Quarterly Institutional 13F Update (Q2 2026)

GPCR ranks #3051 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

GPCR is a top-conviction position for NEXTBio Capital Management LP — at 7.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in GPCR belongs to FMR LLC, but the position matters far more to NEXTBio Capital Management LP, who has 7.7% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

American Century Companies Inc has added to its GPCR position for two straight quarters, increasing it by $55.0M to reach $90.3M today.

Price T Rowe Associates Inc /md/ has trimmed its GPCR position for two straight quarters, cutting it by $70.8M while still holding $45.4M.

GPCR is down 1.1% today, but institutions show net buying of $157.8M this quarter — a divergence between today's price move and the underlying institutional flow.

GPCR reported a net loss of $141.2M in its latest fiscal year.

• Not yet profitable — net loss of $141.2M in the latest fiscal year
• Net income declined year over year, from -$122.5M to -$141.2M
• Operating cash flow was negative, using $222.2M in cash
• Current ratio of 24.81x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.04x equity — within a conventional range